Wexford, PA, (August 13, 2015) InteloMed, Inc., an emerging leader and developer of hardware and software for non-invasive cardiovascular monitoring, will present at the Board of Nephrology Examiners Nursing and Technology (“BONENT”) Northeast Regional Seminar in Newark, New Jersey on August 16. BONENT is a leading professional education and credentialing organization in nephrology with membership of over 7,000 nurses and technicians.
Lori Poole, RN, MSN and Helene Colaizzi, DPM of InteloMed will present on the Company’s lead product CVInsight™, a non-invasive, easy-to-use platform for monitoring patient cardiovascular stress during hemodialysis treatment and informing clinical decisions.
“BONENT is committed to improving care for nephrology patients globally,” commented RJ Picciano BA, CHT, OCDT, CHBT, BONENT’s President. She is also the Fluid Volume Educator at the Centers for Dialysis Care in Cleveland, OH, where the CVInsight™ Platform is currently used. “It is important that we educate our members about new advances in monitoring cardiovascular response during hemodialysis in order to increase patient safety and treatment efficacy.”
“Cardiovascular events during hemodialysis treatments are common and can be deleterious to the patient and costly to the health care system,” stated Jill Schiaparelli, Intelomed President and CEO. “We’re very pleased to have this opportunity to share the benefits of the CVInsight™ Platform with the BONENT membership.”
The Board of Nephrology Examiners Nursing Technology (“BONENT”) is a non-profit organization promoting excellence in the quality of care of nephrology patients in the United States and many countries around the world. BONENT serves as a trusted representative voice to policy makers by urging legislative and regulatory movement toward meaningful training, certification and credentialing of nephrology practitioners. Recognized since 1974 as the leading, independent professional certification body, BONENT identifies safe and competent practitioners in nephrology by providing highly regarded, comprehensive specialty examinations and credentialing.
For more information about BONENT, visit www.Bonent.org.
InteloMed is redefining the standard of care in intelligent cardiovascular monitoring in hospitals and health care facilities through its non-invasive CVInsight™ Platform. The CVInsight™ Platform provides real-time insights on the stress level of the cardiovascular system to inform clinical decisions which, as part of a well-managed care plan, may lead to earlier detection of cardiovascular decline, earlier intervention, decreased hospitalization and improved patient outcomes. The CVInsight™ Platform has functionality in hospital and outpatient settings and has clinical applications in multiple areas including hemodialysis, heart failure, and the surgical continuum.
For more information, visit www.InteloMed.com.
Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.
PR / Media Contact: